keyword
MENU ▼
Read by QxMD icon Read
search

Aripiprazole

keyword
https://www.readbyqxmd.com/read/29325225/influence-of-cyp2d6-cyp3a4-cyp3a5-and-abcb1-polymorphisms-on-pharmacokinetics-and-safety-of-aripiprazole-in-healthy-volunteers
#1
Carmen Belmonte, Dolores Ochoa, Manuel Román, Miriam Saiz-Rodríguez, Aneta Wojnicz, Clara Isabel Gómez-Sánchez, Samuel Martín-Vilchez, Francisco Abad-Santos
The aim of this study was to investigate the effect of polymorphisms in cytochrome P450 (CYP) 2D6, CYP3A4 and CYP3A5 enzymes and in P-glycoprotein (P-gp) on the pharmacokinetics and safety of aripiprazole and, its active metabolite, dehydro-aripiprazole, in 148 healthy volunteers from 6 bioequivalence trials receiving a single oral dose of aripiprazole. The plasma concentrations of both analytes were measured by LC-MS/MS. CYP2D6 (*3,*4,*5,*6,*7,*9 and copy number variations), CYP3A4 (*20 and *22), CYP3A5*3 and C3435T, C1236T and G2677T/A in ABCB1 gene were determined...
January 11, 2018: Basic & Clinical Pharmacology & Toxicology
https://www.readbyqxmd.com/read/29324468/switching-antipsychotic-treatment-to-aripiprazole-in-psychotic-patients-with-neuroleptic-induced-tardive-dyskinesia-a-24-week-follow-up-study
#2
Chia-Hsiang Chan, Hung-Yu Chan, Yen-Ching Chen
Aripiprazole is a second-generation antipsychotics, acting as a partial dopamine D2 receptor agonist. Previous studies on aripiprazole for tardive dyskinesia (TD) treatment were limited and inconclusive. This study was aimed to examine the effectiveness of aripiprazole in psychotic patients with a pre-existing TD. This was an open-label 24-week prospective cohort study conducted in a public mental hospital in Northern Taiwan from January 2009 to February 2010.Psychotic patients were cross-titrated of prior antipsychotics with aripiprazole, and the severity of TD was assessed at baseline and at weeks 2, 4, 8, 12, 16, 20, and 24...
January 10, 2018: International Clinical Psychopharmacology
https://www.readbyqxmd.com/read/29324280/effective-phospholipids-removing-microelution-solid-phase-extraction-lc-ms-ms-method-for-simultaneous-plasma-quantification-of-aripiprazole-and-dehydro-aripiprazole-application-to-human-pharmacokinetic-studies
#3
Aneta Wojnicz, Carmen Belmonte, Dora Koller, Ana Ruiz-Nuño, Manuel Román, Dolores Ochoa, Francisco Abad Santos
A simple liquid chromatography-tandem mass spectrometry (LC-MS/MS) method has been developed and validated for simultaneous quantification of aripiprazole and its active metabolite, dehydro-aripiprazole, in human plasma. Stable isotopically labeled aripiprazole, aripiprazole-D8, has been used as the internal standard (IS) for both analytes. Only 200 μl of human plasma was needed for analyte extraction, using effective phospholipids-eliminating three-step microelution-solid-phase extraction (SPE, Oasis PRiME HLB 96-well μElution Plate)...
December 28, 2017: Journal of Pharmaceutical and Biomedical Analysis
https://www.readbyqxmd.com/read/29313261/enhancement-of-in-vivo-efficacy-and-oral-bioavailability-of-aripiprazole-with-solid-lipid-nanoparticles
#4
Silki, Vivek Ranjan Sinha
Aripiprazole (ARP), a second-generation or atypical antipsychotic, is poorly soluble and undergoes extensive hepatic metabolism and P-glycoprotein efflux which lead to reduced in vivo efficacy and increased dose-related side effects. To enhance in vivo efficacy and oral bioavailability of aripiprazole, aripiprazole-loaded solid lipid nanoparticles (SLNs) were developed using tristearin as solid lipid. Tween 80 and sodium taurocholate were used as surfactants to prepare SLNs using microemulsification method...
January 8, 2018: AAPS PharmSciTech
https://www.readbyqxmd.com/read/29308601/aripiprazole-intramuscular-for-psychosis-induced-aggression-or-agitation-rapid-tranquillisation
#5
REVIEW
Edoardo G Ostinelli, Salwan Jajawi, Styliani Spyridi, Kamlaj Sayal, Mahesh B Jayaram
BACKGROUND: People experiencing psychosis may become aggressive. Antipsychotics, such as aripiprazole in intramuscular form, can be used in such situations. OBJECTIVES: To evaluate the effects of intramuscular aripiprazole in the treatment of psychosis-induced aggression or agitation (rapid tranquillisation). SEARCH METHODS: On 11 December 2014 and 11 April 2017, we searched the Cochrane Schizophrenia Group's Study-based Register of Trials which is based on regular searches of CINAHL, BIOSIS, AMED, Embase, PubMed, MEDLINE, PsycINFO, and registries of clinical trials...
January 8, 2018: Cochrane Database of Systematic Reviews
https://www.readbyqxmd.com/read/29303800/prescribing-trends-of-atypical-antipsychotic-drugs-in-an-outpatient-unit-of-a-child-and-adolescent-clinic-in-turkey
#6
Çiğdem Yektaş, Ali Evren Tufan
OBJECTIVE: Use of antipsychotic agents in the management of various psychopathologies in Child and Adolescent Psychiatric practice is gradually increasing. This study aimed to evaluate the sociodemographic and clinical features of children and adolescents who applied to an outpatient clinic of child and adolescent psychiatry department in Turkey and were prescribed atypical antipsychotics. METHOD: Patients with prescription codes of ATC N05A (except N05AN lithium) were accepted to denote those with atypical antipsychotic treatment...
January 5, 2018: Clinical Neuropharmacology
https://www.readbyqxmd.com/read/29303082/aripiprazole-loaded-polymeric-micelles-fabrication-optimization-and-evaluation-using-response-surface-method
#7
Payal Hasmukhlal Patil, Pooja R Wankhede, H S Mahajan, Laxmikant Zawar
AIMS AND BACKGROUND: The fundamental objective of current study was to encapsulate Aripiprazole (ARP) within Pluronic F127 micelles to improve its aqueous solubility. The recent patents on Aripiprazole (JP2013136621) and micelles (WO2016004369A1) facilitated selection of drug and polymer. MATERIALS AND METHODS: The drug loaded micelles were prepared by thin-film hydration technique. Response surface method (RSM) was used for optimization of micellar formulation...
January 4, 2018: Recent Patents on Drug Delivery & Formulation
https://www.readbyqxmd.com/read/29299155/neuroprotection-by-aripiprazole-against-%C3%AE-amyloid-induced-toxicity-by-p-ck2%C3%AE-activation-via-inhibition-of-gsk-3%C3%AE
#8
So Youn Park, Hwa Kyoung Shin, Won Suk Lee, Sun Sik Bae, Koanhoi Kim, Ki Whan Hong, Chi Dae Kim
Psychosis is reported over 30% of patients with Alzheimer's disease (AD) in clinics. Aripiprazole is an atypical antipsychotic drug with partial agonist activity at the D2 dopamine and 5-HT1A receptors with low side-effect profile. We identified aripiprazole is able to overcome the amyloid-β (Aβ)-evoked neurotoxicity and then increase the cell viability. This study elucidated the mechanism(s) by which aripiprazole ameliorates Aβ1-42-induced decreased neurite outgrowth and viability in neuronal cells. Pretreatment with aripiprazole increased Brain-derived neurotrophic factor (BDNF) mRNA and protein expressions in N2a cells...
December 15, 2017: Oncotarget
https://www.readbyqxmd.com/read/29290022/omega-3-fatty-acids-supplementation-with-lithium-and-aripiprazole-for-improving-the-balance-of-circulating-hormones-and-brain-neurotransmitters-in-manic-mice-model
#9
Pandiyan Arunagiri, Elumalai Balamurugan, Murugesan Saravanakumar, Mackraj Irene
The present study was designed to evaluate the combined effect of lithium and aripiprazole supplemented with omega-3 fatty acids in methylphenidate (MPD)-induced manic mice. Swiss albino mice were administered with MPD or saline for 14 days, and based on changes in behavioral activities animals were treated with lithium, aripiprazole, and omega-3 fatty acids from the 8th day. Behavioral patterns were analyzed by video tracking. Thyroxine, follicle-stimulating hormone (FSH), luteinizing hormone (LH), and testosterone levels were assayed in serum using ELISA kits...
December 30, 2017: Naunyn-Schmiedeberg's Archives of Pharmacology
https://www.readbyqxmd.com/read/29284368/estimation-of-the-relative-difference-or-relative-risk-reduction-under-the-sequential-parallel-comparison-design
#10
Kung-Jong Lui
To increase power or reduce the number of patients needed in trials studying treatments for psychiatric or mental disorders with a high placebo response rate, we may consider use of the sequential parallel comparison design proposed elsewhere. Because statistical significance does not necessarily imply that the difference between treatment and placebo is of clinical importance, it is always of importance to quantify the treatment effect in clinical trials. When the patient responses are dichotomous, the treatment and other covariates effects are not likely additive...
January 1, 2017: Statistical Methods in Medical Research
https://www.readbyqxmd.com/read/29283140/aripiprazole-induced-transient-myopia-a-rare-entity
#11
K V Praveen Kumar, P Chiranjeevi, Md Shahid Alam
Aripiprazole is a new drug for the treatment of adults with schizophrenia. Ocular side effects of aripiprazole are very rare. Review of literature revealed few cases of aripiprazole-induced myopia. We report a rare case of aripiprazole-induced transient myopia. A 22-year-old female patient presented to the department of psychiatry with worsening of symptoms of schizophrenia and was started on aripiprazole. She presented with complaints of blurring of vision in both eyes for 1 week which started on the 3rd day following the use of aripiprazole...
January 2018: Indian Journal of Ophthalmology
https://www.readbyqxmd.com/read/29282341/-tourette-syndrome-clinical-features-and-pathophysiology
#12
Yoshiko Nomura
Tourette syndrome (TS) is a neuropsychiatric disorder with the onset in childhood. TS is a form of tic disorders, and characterized by the motor and vocal tics, and comorbidities such as attention deficit hyperkinetic and obsessive compulsive disorders. These symptoms appear age dependently, showing a wax and wane course, and subside or abolish by the late teens. Pathophysiology of TS involves the dysfunction of both motor and non-motor basal ganglia-thalamo-cortical circuitries. The nigrostriatal dopamine (DA) system takes the exponential decrement at the striatum...
December 2017: Brain and Nerve, Shinkei Kenkyū No Shinpo
https://www.readbyqxmd.com/read/29281033/comparing-and-combining-topiramate-and-aripiprazole-on-alcohol-related-outcomes-in-a-human-laboratory-study
#13
Carolina L Haass-Koffler, Kimberly Goodyear, William H Zywiak, Lorenzo Leggio, George A Kenna, Robert M Swift
Aims: The goal of this study was to evaluate the efficacy of topiramate up to 200 mg/day and of aripiprazole up to 15 mg/day, alone and combined, in reducing alcohol-related outcomes in a human laboratory study. Method: This was a 5 week, between-subject, double-blind, placebo-controlled human laboratory study with topiramate [0 mg/day (placebo), 100 mg/day, 200 mg/day] and aripiprazole [0 mg/day (placebo), 7.5 mg/day, 15 mg/day] in 90 non-treatment seeking, heavy drinking, alcohol-dependent individuals...
December 21, 2017: Alcohol and Alcoholism: International Journal of the Medical Council on Alcoholism
https://www.readbyqxmd.com/read/29280533/comparative-effects-of-aripiprazole-and-selected-antipsychotic-drugs-on-lipid-peroxidation-in-plasma
#14
Anna Dietrich-Muszalska, Jolanta Kolińska-Łukaszuk
AIM: The aim of the present study was to evaluate and compare the effects of a new antipsychotic aripiprazole, unique due to its mechanism of action, with the effects of selected antipsychotic drugs such as quetiapine, olanzapine, clozapine, risperidone and ziprasidone (at the final concentrations corresponding to clinically effective doses used for the treatment of acute episodes of schizophrenia) on lipid peroxidation in human plasma measured by the level of TBARS (thiobarbituric acid reactive substances), which is a marker of oxidative stress...
December 27, 2017: Psychiatry and Clinical Neurosciences
https://www.readbyqxmd.com/read/29278206/a-systematic-review-of-evidence-based-treatment-strategies-for-obsessive-compulsive-disorder-resistant-to-first-line-pharmacotherapy
#15
Umberto Albert, Donatella Marazziti, Gabriele Di Salvo, Francesca Solia, Gianluca Rosso, Giuseppe Maina
BACKGROUND: Serotonin reuptake inhibitors (SRIs) and cognitive-behavioral psychotherapy (CBT) are first-line treatments for obsessive-compulsive disorder (OCD). However, a significant proportion of patients do not respond satisfactorily to first-choice treatments. Several options have been investigated for the management of resistant patients. OBJECTIVE: The aim of the present paper is to systematically review the available literature concerning the strategies for the treatment of resistant adult patients with OCD...
December 22, 2017: Current Medicinal Chemistry
https://www.readbyqxmd.com/read/29276354/multidimensional-approaches-for-a-case-of-severe-adult-obsessive-compulsive-disorder
#16
Zhongyong Shi, Xinchun Mei, Yingbo Zhu, Yu Shuai, Yupeng Chen, Yujie Wu, Yuan Shen
Obsessive-compulsive disorder (OCD) is a chronic, distressing and substantially impairing neuropsychiatric disorder, characterized by obsessions or compulsions. The current case describes a 44-year-old adult female diagnosed with OCD. The patient had an incomplete response to several SSRIs alone during her past treatment, and led a poor-quality life for at least three years. Current multidimensional approaches, including combined cognitive behavioral therapy (CBT) and the Selective Serotonin Reuptake Inhibitor (SSRI, Sertraline) with a small dose of antipsychotics (Aripiprazole) for augmentation, as well as familial support and resources from the internet were provided for the patient for six months...
October 25, 2017: Shanghai Archives of Psychiatry
https://www.readbyqxmd.com/read/29275963/qt-prolongation-torsades-de-pointes-and-psychotropic-medications-a-5-year-update
#17
REVIEW
Scott R Beach, Christopher M Celano, Alan M Sugrue, Caitlin Adams, Michael J Ackerman, Peter A Noseworthy, Jeff C Huffman
BACKGROUND: Some psychotropic medications have been associated with prolongation of the QT interval and QT prolongation, especially in those with medical illness, and are linked to lethal ventricular arrhythmias, such as Torsades de Pointes (TdP). In 2013, we published a review of QT prolongation, TdP, and psychotropic medications. OBJECTIVE: We provide an update over the past 5 years on the specific concerns most relevant to clinicians who see medically ill patients...
November 3, 2017: Psychosomatics
https://www.readbyqxmd.com/read/29275156/aripiprazole-use-during-pregnancy-peripartum-and-lactation-a-systematic-literature-search-and-review-to-inform-clinical-practice
#18
REVIEW
A Cuomo, A Goracci, A Fagiolini
BACKGROUND: Aripiprazole is used relatively frequently in women with bipolar disorder or schizophrenia in childbearing years, owing to its efficacy and relatively favorable side effect profile. As is the case for other psychotropic medications, for ethical reasons, no prospective randomized placebo controlled trial to assess aripiprazole safety during pregnancy has ever been conducted. However, animal data are available and the amount of exposure and outcome data for human fetuses and infants has recently increased, providing published prospective safety data in relatively large numbers of pregnant women treated with aripiprazole...
December 14, 2017: Journal of Affective Disorders
https://www.readbyqxmd.com/read/29274869/neuromodulators-for-functional-gi-disorders-disorders-of-gut-brain-interaction-a-rome-foundation-working-team-report
#19
REVIEW
Douglas A Drossman, Jan Tack, Alexander C Ford, Eva Szigethy, Hans Törnblom, Lukas Van Oudenhove
BACKGROUND AND AIMS: Central neuromodulators (antidepressants, antipsychotics and other CNS targeted medications) are increasingly used for treatment of functional GI disorders (FGIDs), now recognized as disorders of gut-brain interaction. However, the available evidence and guidance for the use of central neuromodulators in these conditions is scanty and incomplete. In this Rome Foundation Working Team report, a multidisciplinary team summarized available research evidence and clinical experience to provide guidance and treatment recommendations...
December 21, 2017: Gastroenterology
https://www.readbyqxmd.com/read/29274734/antipsychotics-and-mortality-in-a-nationwide-cohort-of-29-823-patients-with-schizophrenia
#20
Heidi Taipale, Ellenor Mittendorfer-Rutz, Kristina Alexanderson, Maila Majak, Juha Mehtälä, Fabian Hoti, Erik Jedenius, Dana Enkusson, Amy Leval, Jan Sermon, Antti Tanskanen, Jari Tiihonen
INTRODUCTION: It has remained controversial if antipsychotic treatment is associated with increased or decreased mortality among patients with schizophrenia, and if there are any clinically meaningful differences between specific agents and routes of administration. METHODS: We linked prospectively gathered nationwide register-based data during 2006-2013 to study all-cause mortality among all patients aged 16-64years with schizophrenia in Sweden (N=29,823 in total; N=4603 in the incident cohort)...
December 20, 2017: Schizophrenia Research
keyword
keyword
4828
1
2
Fetch more papers »
Fetching more papers... Fetching...
Read by QxMD. Sign in or create an account to discover new knowledge that matter to you.
Remove bar
Read by QxMD icon Read
×

Search Tips

Use Boolean operators: AND/OR

diabetic AND foot
diabetes OR diabetic

Exclude a word using the 'minus' sign

Virchow -triad

Use Parentheses

water AND (cup OR glass)

Add an asterisk (*) at end of a word to include word stems

Neuro* will search for Neurology, Neuroscientist, Neurological, and so on

Use quotes to search for an exact phrase

"primary prevention of cancer"
(heart or cardiac or cardio*) AND arrest -"American Heart Association"